Last reviewed · How we verify
Episcleral Celecoxib — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Episcleral Celecoxib (Episcleral Celecoxib) — Targeted Therapy Technologies, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Episcleral Celecoxib TARGET | Episcleral Celecoxib | Targeted Therapy Technologies, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Episcleral Celecoxib CI watch — RSS
- Episcleral Celecoxib CI watch — Atom
- Episcleral Celecoxib CI watch — JSON
- Episcleral Celecoxib alone — RSS
Cite this brief
Drug Landscape (2026). Episcleral Celecoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/episcleral-celecoxib. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab